Effect of a conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway

Chinese Medical Journal

Volumn 122, Issue 4, 2009, Pages 460-465

  Liu, Hong ^a   Ye, Lin ^b   Wang, Qing Wei ^a   Yan, Qiu Xia ^a   Yu, Jin Ming ^c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Apoptosis; Carcinoma; Hepatocellular; p97 valosin containing protein; Peptides; Proteasome; Ubiquitin

Indexed keywords

ADENOSINE TRIPHOSPHATASE; HEPATITIS B VIRUS X PROTEIN; PEPTIDASE; PROTEASOME; PROTEIN P97; LIPOPEPTIDE; NUCLEAR PROTEIN; P97 ATPASE; PAM LYS(0) ARG(1) PRO(2) PRO(3) GLY(4) PHE(5) SER(6) PRO(7) PHE(8) ARG(9) OH; PAM-LYS(0)-ARG(1)-PRO(2)-PRO(3)-GLY(4)-PHE(5)-SER(6)-PRO(7)-PHE(8)-ARG(9)-OH; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN HEPG2; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KUNITZ DOMAIN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; CELL CYCLE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; MOUSE; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; LIPOPEPTIDES; MICE; NUCLEAR PROTEINS; TRANS-ACTIVATORS; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 65649135452     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.04.0019     Document Type: Article

References (32)

1. Heathcote EJ. Treatment of hepatitis B: the next five years. Clin Med 2007; 7: 472-477.
2. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3-8.
3. Keasler VV, Hodgson AJ, Madden CR, Slagle BL. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J Virol 2007; 81: 2656-2662.
4. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 2001; 36: 651-660.
5. Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006; 97: 977-983.
6. Thabrew MI, Mitry RR, Morsy MA, Hughes RD. Cytotoxic effects of a decoction of Nigella sativa, Hemidesmus indicus and Smilax glabra on human hepatoma HepG2 cells. Life Sci 2005; 77: 1319-1330.
7. Huang J, Kwong J, Sun EC, Liang TJ. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol 1996; 70: 5582-5591.
8. Zhang Z, Torii N, Furusaka A, Malayaman N, Hu Z, Liang TJ. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex. J Biol Chem 2000; 275: 15157-15165.
9. Armon T, Ganoth D, Hershko A. Assembly of the 26 S complex that degrades proteins ligated to ubiquitin is accompanied by the formation of ATPase activity. J Biol Chem 1990; 265: 20723-20726.
10. Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J Virol 1999; 73: 7231-7240.
11. Asai T, Tomita Y, Nakatsuka S, Hoshida Y, Myoui A, Yoshikawa H, et al. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002; 93: 296-304.
12. Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Kidogami S, Miyata H, et al. Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma. Clin Cancer Res 2004; 10: 5558-5565.
13. Takada S, Koike K. X protein of hepatitis B virus resembles a serine protease inhibitor. Jpn J Cancer Res 1990; 81: 1191-1194.
14. Takada S, Kido H, Fukutomi A, Mori T, Koike K. Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor. Oncogene 1994; 9: 341-348.
15. Kanda T, Yokosuka O, Imazeki F, Yamada Y, Imamura T, Fukai K, et al. Hepatitis B virus X protein (HBx)-induced apoptosis in HuH-7 cells: influence of HBV genotype and basal core promoter mutations. Scand J Gastroenterol 2004; 39: 478-485.
16. Wang QW, Lu HL, Song CC, Liu H, Xu CG. Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel. World J Gastroenterol 2005; 11: 4003-4007.
17. Akiyama Y, Kihara A, Tokuda H, Ito K. FtsH (HflB) is an ATP-dependent protease selectively acting on SecY and some other membrane proteins. J Biol Chem 1996; 271: 31196-31201.
18. Yakushiji Y, Yamanaka K, Ogura T. Identification of a cysteine residue important for the ATPase activity of C. elegans fidgetin homologue. FEBS Lett 2004; 578: 191-197.
19. Chen WN, Oon CJ. Human hepatitis B virus mutants: significance of molecular changes. FEBS Lett 1999; 453: 237-242.
20. Takada S, Tsuchida N, Kobayashi M, Koike K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J Cancer Res Clin Oncol 1995; 121: 593-601.
21. Miao J, Chen GG, Chun SY, Lai PP. Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Lett 2006; 236: 115-124.
22. Chen HY, Tang NH, Lin N, Chen ZX, Wang XZ. Hepatitis B virus X protein induces apoptosis and cell cycle deregulation through interfering with DNA repair and checkpoint responses. Hepatol Res 2008; 38: 174-182.
23. Chen WN, Oon CJ, Goo KS. Hepatitis B virus X protein in the proteasome of mammalian cells: defining the targeting domain. Mol Biol Rep 2001; 28: 31-34.
24. Seeger C. The hepatitis B virus X protein: the quest for a role in viral replication and pathogenesis. Hepatology 1997; 25: 496-498.
25. Hoffman L, Rechsteiner M. Nucleotidase activities of the 26 S proteasome and its regulatory complex. J Biol Chem 1996; 271: 32538-32545.
26. Kanayama HO, Tamura T, Ugai S, Kagawa S, Tanahashi N, Yoshimura T, et al. Demonstration that a human 26S proteolytic complex consists of a proteasome and multiple associated protein components and hydrolyzes ATP and ubiquitin-ligated proteins by closely linked mechanisms. Eur J Biochem 1992; 206: 567-578.
27. Ugai S, Tamura T, Tanahashi N, Takai S, Komi N, Chung CH, et al. Purification and characterization of the 26S proteasome complex catalyzing ATP-dependent breakdown of ubiquitin-ligated proteins from rat liver. J Biochem 1993; 113: 754-768.
28. Wang Q, Song C, Li CC. Hexamerization of p97-VCP is promoted by ATP binding to the D1 domain and required for ATPase and biological activities. Biochem Biophys Res Commun 2003; 300: 253-260.
29. Song C, Wang Q, Li CC. Characterization of the aggregation-prevention activity of p97/valosin-containing protein. Biochemistry 2007; 46: 14889-14898.
30. Song C, Wang Q, Li CC. ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J Biol Chem 2003; 278: 3648-3655.
31. Wójcik C, Yano M, DeMartino GN. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci 2004; 117: 281-292.
32. Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Monden M. Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol 2004; 11: 697-704.